Menarini Group and SciClone Pharmaceuticals ink deal to commercialize drug in China; Celsion to change its name
Menarini’s Asia-Pacific subsidiary and SciClone Pharmaceuticals have entered into a licensing agreement to develop and eventually commercialize the drug Vaborem in China.
The deal is …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
